1. What Is ISPOR Value Flower?
The ISPOR Value Flower is a health-economic value-assessment framework that identifies benefits and costs that conventional cost-effectiveness analysis may overlook. It helps decision makers ask a broader question: beyond average health improvement and net treatment cost, what else matters when evaluating a medical technology?
ISPOR stands for the International Society for Pharmacoeconomics and Outcomes Research, now branded as The Professional Society for Health Economics and Outcomes Research. The “flower” depicts dimensions of value as petals surrounding a central value concept. It is an inventory for assessment, not a ready-made scoring formula.
Consultants can use it to structure evidence reviews and executive discussions. For health payers, the practical application is deciding whether, for whom, and under what conditions to cover a treatment—not simply whether its acquisition price is high.
2. Origin and Background
The framework appeared in February 2018 in “Defining Elements of Value in Health Care—A Health Economics Approach,” part of ISPOR’s Special Task Force report on US value assessment. The article’s authors were Darius Lakdawalla, Jalpa Doshi, Louis Garrison, Charles Phelps, Anirban Basu, and Patricia Danzon.
ISPOR formed the task force in 2016 amid the emergence of several US medicine-value frameworks. Its purpose was to examine those approaches through health economics and clarify their differing decision contexts. The flower assembled concepts from earlier research rather than inventing every value element.
Its original emphasis was coverage and reimbursement assessment, particularly inclusion in an insurance benefit package. Subsequent research has examined how to quantify additional elements and incorporate them into deliberation. That development has not produced universal agreement about which petals to include or how much weight to give them.
3. How ISPOR Value Flower Works
The original flower contains 12 elements: two core elements, two commonly considered but inconsistently incorporated elements, and eight potentially novel elements. Their position in the diagram does not imply equal importance or independent, additive value.
The 12 original petals
| Petal | Meaning and healthcare interpretation |
|---|---|
| Quality-adjusted life-years | Health gains combining length and quality of life; account for treatment harms as well as benefits. |
| Net costs | Incremental costs after offsets, including acquisition, administration, adverse-event management, and subsequent care. Together with health gains, these form the conventional core. |
| Productivity | Changes in paid and unpaid work, potentially affecting patients and caregivers. |
| Adherence-improving factors | Features that improve treatment use, such as simpler administration; associated health gains may already be captured in the model. |
| Reduction in uncertainty | Value from knowing prognosis or likely treatment response, beyond health gains from better-targeted care. |
| Fear of contagion | Value from reducing infection-related anxiety and its consequences, distinct from avoided infections themselves. |
| Insurance value | Protection against future financial and health risk, including value to people not currently affected. |
| Severity of disease | Additional value or priority attached to gains for people who are worse off, beyond the size of the health gain alone. |
| Value of hope | Preferences for a credible chance of exceptional benefit, rather than unsupported optimism. |
| Real option value | Living long enough to benefit from future innovations, beyond survival benefits already modeled. |
| Equity | How benefits and burdens are distributed, including whether access arrangements reduce or widen disparities. |
| Scientific spillovers | Knowledge generated by innovation that benefits subsequent research and technologies. Attribution requires care. |
Use an intervention for a defined patient population against a relevant comparator as the primary unit of analysis. A therapy can have different value profiles across disease stages or treatment lines; assessing the drug name alone obscures those differences.
For each relevant petal, decide whether it is already captured, can be quantified defensibly, belongs in sensitivity analysis, or should remain a qualitative consideration. These are recommended assessment categories, not additional petals. Family and caregiver health effects can also merit attention, but should not be mislabeled as a separate original petal.
4. When to Use ISPOR Value Flower
Consider the framework when a conventional economic assessment leaves important stakeholder concerns unresolved. Suitable questions include whether diagnostic knowledge adds value beyond treatment selection, whether severe disease warrants additional priority, or whether an intervention’s benefits extend to caregivers and people at future risk.
For health systems and hospitals, apply the flower to technology-adoption or treatment-pathway decisions. Pair the assessment with delivery feasibility: pharmacy capacity, specialist staffing, referral arrangements, and outcome monitoring should be checked before committing to adoption.
Required inputs depend on the petals selected. Start with comparative clinical evidence, health-related quality of life, resource use, and costs; add preference research, caregiver evidence, and subgroup information where relevant. Involve clinicians, health economists, finance, pharmacy, and patient representatives.
The flower is especially useful for identifying omitted considerations. It is a poor substitute for clinical-effectiveness assessment, an affordability model, or individual treatment advice. Misleading conclusions arise when teams mix perspectives, assume every petal is positive, or count the same benefit repeatedly. Formal assessment requires more work than an initial workshop screen.
5. How to Apply ISPOR Value Flower: Step-by-Step
Clarify the decision and perspective. Specify whether the committee is deciding coverage, formulary position, adoption, or reimbursement conditions. Define the population, geography, comparator, time horizon, and payer or societal perspective.
Assemble the evidence. Gather comparative outcomes, survival, adverse events, health-state utilities, treatment completion, resource use, and net costs. Identify relevant preference and caregiver evidence. Separate observations from assumptions and manufacturer claims.
Define comparable units. Assess intervention–population combinations, not undifferentiated products. Separate clinically meaningful subgroups where treatment response, prognosis, or access differs. Use consistent comparators and horizons.
Build a petal evidence register. Create one row per original petal, recording relevance, mechanism, affected stakeholder, evidence quality, proposed treatment in the assessment, and possible overlap. Mark irrelevant petals explicitly rather than filling every row with a benefit.
Interpret incremental value. Ask what changes relative to current care. Trace each claimed benefit through its causal pathway. Check whether adherence, anxiety, caregiver effects, or future treatment opportunities already influence modeled outcomes or costs.
Translate findings into action. Develop coverage criteria, evidence-generation priorities, referral support, or contracting options. Keep clinical eligibility, broader value judgments, and affordability visible as separate considerations.
Test uncertainty and alternatives. Vary durability, uptake, eligibility, net price, and future innovation assumptions. Use scenario and sensitivity analysis to identify which assumptions change the funding decision. Include a case without speculative additional value.
Align stakeholders and establish review. Present the evidence register alongside the economic and budget models. Document disagreements and decision rules. Assign owners for missing evidence, implementation activities, and reassessment triggers.
6. Example: ISPOR Value Flower in Action
Fictional case: Harborview Health Plan is evaluating coverage for a new cell therapy for a defined relapsed lymphoma population. Its medical and finance leaders disagree about whether potentially durable benefit justifies the proposed expenditure.
The team compares the therapy with the relevant existing treatment pathway. Its assessment includes survival, quality of life, adverse events, administration, monitoring, and subsequent treatment. Long-term durability remains an explicit assumption rather than an established fact.
The flower identifies several issues requiring further examination. Disease severity is relevant to prioritization. Patient interviews suggest interest in the possibility of unusually long survival, prompting a review of evidence on outcome distributions and preferences—not an automatic “hope premium.” Caregiver work effects belong in a supplementary societal analysis.
Fear of contagion is irrelevant. Scientific spillovers and future-treatment option value lack sufficiently specific evidence for quantification. The team also finds that its model already reflects treatment-completion differences, preventing a second adherence benefit.
Harborview approves coverage for clinically eligible patients, establishes referral assistance, and explores an outcomes-linked rebate subject to feasibility review. Its rationale distinguishes demonstrated benefit, contextual judgments, and unresolved uncertainty.
Where committees remain divided, decision-making support can turn that evidence into documented trade-offs, approval conditions, and an executable reassessment plan.
7. Strengths and Limitations
Strengths
- Broadens the assessment: Prompts questions about value beyond average patient outcomes and medical expenditure.
- Makes omissions visible: Provides a structured way to identify evidence gaps before a coverage decision.
- Improves discussion: Gives clinical, financial, patient, and economic stakeholders a shared vocabulary.
Limitations
The flower does not supply standardized weights, a reimbursement threshold, or proof of clinical benefit. Several petals overlap, and their measurement can depend on elicitation methods and perspective. Supporters favor more comprehensive quantification; critics argue that some elements are better handled through deliberation or other policy mechanisms.
Opportunity cost is particularly important. Funding one intervention can displace care that also delivers hope, productivity, or equity benefits. Adding broader value only to the proposed technology can bias the comparison.
8. Common Pitfalls and How to Avoid Them
- Adding every petal: Relevance is not universal. Require an intervention-specific mechanism before including an element.
- Double counting adherence: Better completion may already improve modeled outcomes. Trace the benefit before adding separate value.
- Confusing hope with efficacy: Evaluate credible outcome distributions and informed preferences; do not substitute promotional optimism for evidence.
- Mixing perspectives: Keep payer expenditure separate from societal productivity and household effects.
- Ignoring displacement: Apply comparable standards to the intervention, comparator, and care forgone.
- Stopping at the diagram: Assign decision owners, implementation requirements, evidence priorities, and review triggers.
These safeguards address the framework’s central operational risks: overlapping concepts, subjective valuation, and inconsistent treatment of broader benefits.
9. How ISPOR Value Flower Relates to Other Frameworks
Cost-effectiveness analysis: Establish the comparative health-and-cost core first. Use the flower alongside it to examine potentially omitted elements, not to discard unfavorable results.
Budget impact analysis: Evaluate expenditure consequences for the relevant payer population. This answers an affordability question that broader value assessment does not resolve.
Multicriteria decision analysis: Use this when explicit trade-offs across criteria are needed. The flower can help identify candidate criteria, but it does not provide their weights or validate their independence.
Generalized Risk-Adjusted Cost-Effectiveness, or GRACE: Consider this alongside the flower when risk preferences, disease severity, and uncertain outcomes materially affect valuation. It offers a more integrated analytical treatment than independently adding premiums for related petals.
10. Key Takeaways
- The flower is a value inventory, not a pricing calculator.
- Assess defined patient populations against relevant alternatives.
- Distinguish modeled benefits from genuinely additional value.
- Keep broader value, affordability, and delivery feasibility separate.
- Convert the assessment into decisions, evidence priorities, and review triggers.
11. FAQs About ISPOR Value Flower
Is the ISPOR Value Flower still relevant today?
Yes, as a structured assessment tool. Research continues to develop measurement approaches, while debate persists about whether particular elements should affect economic calculations, deliberation, or pricing. It should not be treated as a settled reimbursement formula.
Must every assessment include all 12 petals?
No. Screen all 12, then investigate those relevant to the intervention and decision. Document exclusions and distinguish “irrelevant” from “potentially important but unsupported.”
What is the minimum useful data?
Begin with a defined population, comparator, comparative outcomes, resource use, and costs. For additional value claims, identify the affected stakeholder, causal mechanism, supporting evidence, and potential overlap with the existing model.
Can smaller healthcare organizations use it?
Yes. Start with a concise evidence register and a multidisciplinary discussion. Use the flower to prioritize questions, then commission specialist analysis only where an unresolved issue could materially change the decision.
